FDA intervenes for 3rd time in Solid Biosciences’ Duchenne drug tests

FDA officials have halted a Phase 1-2 trial of Solid’s gene-targeting treatment after a subject taking a higher dose of the drug experienced a drop in red blood cells, kidney injury and heart issues.